Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Politz

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The FEBS Journal|January 7, 2005
Androgen receptor function is modulated by the tissue-specific AR45 variantIsabelle Ahrens-Fath, Oliver Politz, Christoph Geserick, et al.
The International Journal of Biochemistry & Cell Biology|March 27, 2007
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agentHolger Hess-Stumpp, Tomke Ute Bracker, David Henderson, et al.
International Journal of Molecular Sciences|February 11, 2023
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer TreatmentFabio Raith, Daniel H O'Donovan, Clara Lemos, et al.
Melanoma Research|April 29, 2015
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assaysKatharina C Kaehler, Oliver Politz, David Henderson, et al.
Investigational New Drugs|December 29, 2011
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor modelsSharon L Longo, David J Padalino, Sandra McGillis, et al.
International Journal of Oncology|February 13, 2019
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinomaHung Huynh, Richard Ong, Kah Yong Goh, et al.
Molecular Cancer Therapeutics|May 7, 2020
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal TumorAlfonso García-Valverde, Jordi Rosell, Garazi Serna, et al.
BMC Cancer|August 13, 2016
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detectionMarion Rudolph, Tobias Anzeneder, Anke Schulz, et al.
Oncotarget|October 28, 2020
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancerKonrad Klinghammer, Oliver Politz, Theresa Eder, et al.
Clinical and Experimental Medicine|November 7, 2023
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responsesSimon Heller, Sarah Glaeske, Katja Gluske, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The FEBS Journal|January 7, 2005
Androgen receptor function is modulated by the tissue-specific AR45 variantIsabelle Ahrens-Fath, Oliver Politz, Christoph Geserick, et al.
The International Journal of Biochemistry & Cell Biology|March 27, 2007
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agentHolger Hess-Stumpp, Tomke Ute Bracker, David Henderson, et al.
International Journal of Molecular Sciences|February 11, 2023
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer TreatmentFabio Raith, Daniel H O'Donovan, Clara Lemos, et al.
Melanoma Research|April 29, 2015
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assaysKatharina C Kaehler, Oliver Politz, David Henderson, et al.
Investigational New Drugs|December 29, 2011
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor modelsSharon L Longo, David J Padalino, Sandra McGillis, et al.
International Journal of Oncology|February 13, 2019
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinomaHung Huynh, Richard Ong, Kah Yong Goh, et al.
Molecular Cancer Therapeutics|May 7, 2020
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal TumorAlfonso García-Valverde, Jordi Rosell, Garazi Serna, et al.
BMC Cancer|August 13, 2016
AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detectionMarion Rudolph, Tobias Anzeneder, Anke Schulz, et al.
Oncotarget|October 28, 2020
Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancerKonrad Klinghammer, Oliver Politz, Theresa Eder, et al.
Clinical and Experimental Medicine|November 7, 2023
Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responsesSimon Heller, Sarah Glaeske, Katja Gluske, et al.
Pageof 2